Hostname: page-component-76d6cb85b7-8p85h Total loading time: 0 Render date: 2026-07-25T17:12:19.815Z Has data issue: false hasContentIssue false

Topical levocabastine for the treatment of perennial allergic rhinitis

Published online by Cambridge University Press:  29 June 2007

Samy Elwany*
Affiliation:
Department of Otolaryngology – Head and Neck Surgery, Alexandria University School of Medicine, Alexandria, Egypt.
Mohamed Bassiouny
Affiliation:
Department of Otolaryngology – Head and Neck Surgery, Alexandria University School of Medicine, Alexandria, Egypt.
*
Address for correspondence: Samy Elwany, M.D., PO Box 267 (Sidi Gaber), Alexandria, Egypt.

Abstract

The ultrastructure of the nasal mucosa following theuse of intranasal levocabastine was studied in 20 patients suffering from perennial allergic rhinitis. The patients received twice daily 0.05 per cent levocabastine spray with a treatment duration of four weeks. At the end of the treatment period regression of the allergic process was evidenced by progressive reappearance of normal cilia and microvilli on the columnar cells, decrease of intercellular oedema andcytoplasmic vacuoles, increased number of mucous acinar cells, gradualdecrease of vascular congestion, as well as diminished oedema fluid formation. The drug, however, had no effect on mast cell degranulationnor on eosinophilic infiltration. Normalization of the ultrastructural features correlated well with clinical improvement.

Considering the results of the present study, levocabastine nasal spray appears to be an effective treatment for perennial allergic rhinitis and can be used with, or as an alternative to, other anti-allergic medications.

Information

Type
Main Atricles
Copyright
Copyright © JLO (1984) Limited 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable